AMG 655: Interim Phase Ib/II data

Interim data from the ongoing Phase Ib/II trial in 15 patients showed that 10 mg/kg AMG 655 in combination with 6 mg/kg Vectibix panitumumab did not cause any DLTs after a median follow-up of 15.4 we...